Ablynx today announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO).
Effective from 20 June 2017, Dr Ewert will lead the Company’s business development and corporate strategy activities and become a member of the Executive Committee. Dr Ewert has worked for nearly 30 years in the life sciences industry and has held a number of senior business and commercial positions.
Until recently, Dr Ewert headed the Business Development team of the Healthcare division of General Electric and in that capacity executed numerous deals. Prior to that, he worked at Novartis in its Cardiovascular and Metabolism franchise and later moved to the Molecular Diagnostics unit as Head of Strategy, Global BD&L, and M&A. Before joining Novartis, Dr Ewert was CEO of two biotech companies and had been at The Boston Consulting Group serving as an advisor to pharmaceutical and chemical companies.
Dr Ewert holds a PhD in molecular biology from the University of Heidelberg and an MBA from the University of Chicago.
Welcoming Dr Ewert to the team, Dr Edwin Moses, CEO of Ablynx, said: “Markus brings extensive experience in leading business development teams and executing licensing deals and acquisitions. Having held senior positions in big pharma as well as in biotech and consultancy firms, he is ideally suited to become part of our Executive Committee and play an important role in helping Ablynx achieve its business objectives.”
Commenting on his appointment, Dr Ewert added: “I am very excited to join the Ablynx team and lead their business development and strategy activities. Ablynx’s Nanobody® platform has been clearly demonstrated to be a very powerful tool in the development of potentially new and important therapeutics. I am looking forward to strengthening the company’s existing relationships with pharmaceutical companies, creating new partnering and strategic opportunities to further build the product pipeline, and advancing the company.”
Source: Ablynx
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.